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Abstract
Background: With the rise in pre-mature mortality rate from non-communicable disease (NCD), there is a need for
evidence-based interventions. We evaluated existing systematic reviews on effectiveness of integration of
healthcare services, in particular with focus on delivery of care designed to improve health and process outcomes
in people with multi-morbidity, where at least one of the conditions was diabetes or hypertension.
Methods: We searched MEDLINE, EMBASE, Cochrane Library, and Health Evidence to November 8, 2016 and
consulted experts. One review author screened titles, abstracts and two review authors independently screened
short listed full-texts and selected reviews for inclusion. We considered systematic reviews evaluating integration of
care, compared to usual care, for people with multi-morbidity. One review author extracted data and another
author verified it. Two review authors independently evaluated risk of bias using ROBIS and AMSTAR. Inter-rater
reliability was analysed for ROBIS and AMSTAR using Cohen’s kappa and percent agreement. The Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) checklist was used to assess reporting.
Results: We identified five systematic reviews on integration of care. Four reviews focused on comorbid diabetes
and depression and two covered hypertension and comorbidities of cardiovascular disease, depression, or diabetes.
Interventions were poorly described. The health outcomes evaluated included risk of all-cause mortality, measures
of depression, cholesterol levels, HbA1c levels, effect of depression on HbA1c levels, symptom improvement,
systolic blood pressure, and hypertension control. Process outcomes included access and utilisation of healthcare
services, costs, and quality of care. Overall, three reviews had a low and medium risk of bias according to ROBIS and
AMSTAR respectively, while two reviews had high risk of bias as judged by both ROBIS and AMSTAR. Findings have
demonstrated that collaborative care in general resulted in better health and process outcomes when compared to
usual care for both depression and diabetes and hypertension and diabetes.
Conclusions: Several knowledge gaps were identified on integration of care for comorbidities with diabetes and/or
hypertension: limited research on this topic for hypertension, limited reviews that included primary studies based in
low-middle income countries, and limited reviews on collaborative care for communicable and NCDs.
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Background
Globally, the number of deaths due to non-communicable
diseases (NCDs) is rising [1]. Amongst NCDs, cardiovas-
cular diseases were the leading cause of death in 2016,
with 17.6 million deaths globally, while deaths due to dia-
betes mellitus increased by 31% from 2006 to 2016. In
addition, NCDs accounted for most (80.6%) of years lived
with disability (YLD) in 2016, with an increase of 17.9%
from 2006 to 2016 [2]. While the leading cause of death in
Sub-Saharan Africa (SSA) is still human immunodefi-
ciency virus (HIV)/acquired immunodeficiency syndrome
(AIDS), the recent release of updated results from the
2016 Global Burden of Disease study, brings focus to the
increase of premature deaths caused by NCDs, such as
diabetes and hypertension, and unintentional injury in
SSA [1–3]. Available evidence suggests that the prevalence
of diabetes has increased from less than 1% in the period
of 1960–1980 to 8–13% in the 1990s [4, 5]. On the other
hand, according to a 2005 study, an estimation of 10 to 20
million people out of approximately 650 million people of
the general population in the SSA region were inflicted
with hypertension with some communities reporting a
prevalence rate as high as 38% [6–9].
In addition to the rapid rise in prevalence of both dia-
betes and hypertension in the SSA region, the intricate
link between the two NCDs further emphasizes the im-
portance and magnitude of this global issue. Studies have
found that all persons with hypertension have an elevated
risk of developing diabetes and this risk is considerably in-
creased if the person is obese as well [10–12].
In an effort to support the African health systems in
addressing this emerging problem, a series of
evidence-based interventions will have to be developed
and implemented to treat these co-morbidities. The Col-
laboration for Evidence-Based Healthcare and Public
Health in Africa (CEBHA+) has developed four priority
research questions in order to address this need [13]. Re-
search on models of integrated health care delivery for
hypertension and diabetes has been identified as one of
the priority questions because it may provide the solu-
tion to multiple longstanding issues present in the
healthcare system and the public health approach to
both NCDs and communicable diseases (CDs) such as
the lack of continuity of care, fragmentation of medical
care/treatment process and patient education.
Despite the wide range of definitions on “integration
of care” available in the literature, it could be seen that
they are united by the common goals of “fostering co-
ordination within and between healthcare organizations
in order to improve patient experience, outcomes of
care, and enhance overall efficiency of health systems” as
proposed by Shaw et al. [14]. This was further supported
by Grone and Garcia-Barbero, who defined the term as
“bringing together of inputs, delivery, management and
organization of services as a means [of] improving ac-
cess, quality, user satisfaction and efficiency” [15]. Tak-
ing the varying definitions into account, we decided to
focus on four types of integration of care: horizontal,
vertical, professional (as known as integrated health ser-
vices), and clinical integrations (Table 1). We only con-
centrated our work around these four types of
integration because this study aims to examine integra-
tion at a service-delivery level for primary care, and not
at an organizational or outcome level.
This scoping review aimed to assess the existing evi-
dence in order to identify gaps in current knowledge on
integration of care of hypertension and diabetes. Our
findings will inform an appropriate research question for
a systematic review which will aim to address the
current knowledge gap. In addition, we compared two
instruments used to assess risk of bias in systematic re-
views, namely University of Bristol’s Risk of Bias of Sys-
tematic Reviews tool (ROBIS) and Assessing the
Methodological Quality of Systemic Reviews tool
(AMSTAR). In addition, we assessed reporting of sys-
tematic reviews according to the PRISMA guideline [16].
Methods
The body of evidence in this scoping review was com-
prised solely of systematic reviews, which was defined by
PRISMA as “a review of a clearly formulated question that
uses systematic and explicit methods to identify, select,
and critically appraise relevant research, and to collect and
analyze data from the studies that are included in the re-
view.” [16] Given that the purpose of a scoping review is
to examine the existing literature on a topic and identify
gaps in research, systematic reviews are an appropriate
type of study for inclusion as they are considered the best
form of evidence and provide a summary of existing pri-
mary studies. This evidence formed the basis of our scop-
ing review and allowed for us to assess the scope, identify
the nature, and determine the extent of systematic reviews
available in current literature [17].
Criteria for considering systematic reviews
Articles were included in this scoping review if they met
the following criteria:
 Target population included people with multi-
morbidities, of which diabetes and/or hypertension
was one. Multi-morbidity was defined as having two
or more chronic conditions for an individual.
 Interventions included integration of health care
delivery, which was defined as models of care where
prevention, diagnosis, or treatment of hypertension,
diabetes, or any NCD was combined with the
delivery of health care for any other condition (e.g.
communicable disease, maternal and child care,
Yiu et al. BMC Health Services Research  (2018) 18:481 Page 2 of 17
mental health, etc.). The integration for these care
services may require professional coordination
across several disciplines
 The comparisons included “usual care” as defined
specifically by each study and stand-alone models of
health care delivery, where care was directed only
towards the prevention, diagnosis, or treatment of
hypertension or diabetes.
 Reported outcomes included health outcomes (e.g.
all-cause mortality, disease-specific morbidity) and
process outcomes (e.g. access to care, retention in
care, continuity of care, quality of care, cost of care,
user-views of care recipients).
 Published in English
 We included systematic reviews which had to
include [18, 19]:
A clearly stated set of pre-determined objec-
tives with an explicit, reproducible methodology
Pre-determined criteria for eligibility
A systematic search that attempted to identify
all studies that would meet the eligibility criteria
through searching through at least two data
sources, with at least one of them being an
electronic database
Performed data extraction and risk of bias
assessment
Approach for identifying systematic reviews
Medical Literature Analysis and Retrieval System Online
(MEDLINE) was searched up to November 8, 2016,
using medical subject heading (MeSH) terms (“diabetes
mellitus”, “diabetes insipidus”, “hypertension”, “blood
pressure”, “comorbidity”, “chronic disease”, “delivery of
health care, integrated”, “comprehensive health care”,
and other related terms). The Excerpta Medica database
(EMBASE) was also searched up to November 8, 2016,
using Excerpta Medica Tree (EMTREE) term (“diabetes
mellitus”, “hypertension”, “diabetic hypertension”). The
Cochrane Database of Systematic Reviews, its associated
information management system, Archie, and the Health
Evidence (http://www.healthevidence.org/) database was
similarly searched for existing systematic reviews,
meta-analyses, and evidence-based overviews. The
search was conducted in Issue 11, November 2016 of
the Cochrane Database of Systematic Reviews using the
key terms “diabetes”, “hypertension”, “comorbidity”, and
“delivery of health care, integrated.” Complete search
strategies for all databases are provided in
Additional file 1.
A search for ongoing studies was also conducted in
PROSPERO, an international prospective register of sys-
tematic reviews, in February 2017. The following terms
were used in the search: “collaborat*”, “integrat*”, “comor-
bid*”, “hypertension”, and “diabetes.” We scanned the ref-
erence lists of included systematic reviews to identify
potentially relevant reviews to consider. In addition, we
contacted experts in the field, thus ensuring that we did
not miss any systematic review which may be of relevance.
Selection of systematic reviews and data extraction
All citations and accompanying abstracts retrieved from
the electronic searches were downloaded to an online
referencing manager (RefWorks). Duplicate references
were deleted before the screening process began. One
reviewer (KY) screened the titles and abstracts of studies
identified for potential inclusion and selected studies for
inclusion using the pre-determined criteria. Full texts of
potentially eligible reviews were retrieved and independ-
ently screened by two authors (KY, AR). We resolved
discrepancies through discussions with the third review
author (TY).
Following the study selection process, KY extracted
data from the included studies and AR checked the ex-
tracted data separately. Disagreements in data abstrac-
tion were resolved through discussion and consensus.
The following information was extracted from the in-
cluded studies: Details of the intervention, participants,
the nature of chronic disease/multi-morbidities, pro-
viders, specialist, and primary care providers, clinical set-
ting, study designs, interventions and outcomes. The
results were organized into health outcomes focused on
an individual-level (e.g. all-cause mortality, disease spe-
cific morbidity) and process outcomes focused on a
systems-level (e.g. access to health care, continuity of
care, quality of care, cost of care, user-views of care
recipients).
Table 1 Definitions and examples of types of integration of
care
Type of Integration Definition Examples
Horizontal [38, 39] Relates to strategies
that link similar
levels of care
Physicians join existing
group practices or
multiple groups merge
Vertical [38, 39] Relates to strategies
that link different
levels of care
Various health care professionals,
such as physicians,
nurses, physiotherapists,
collaborate with
hospitals, universities/medical
schools, health
plans, etc.
Professional integration
or integrated health
services [38, 40]
Refers to the extent
to which professionals
coordinate services
across various
disciplines
Nurse practitioners
work with dieticians
to provide care for
patients with diabetes
Clinical integration [38] Refers to the extent
to which care services
are coordinated
Maintaining an open
communication channel
by having dieticians send
a consultation report to
the family physician after
appointment with
their patient
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Assessing risk of bias of systematic reviews
Two reviewers (AR, KY) independently assessed the risk
of bias in each included review using the ROBIS and
AMSTAR tools (Additional files 2 & 3). The ROBIS tool
is a newly developed tool for the assessment of risk of
bias for systematic reviews as opposed to those designed
to assess primary studies [20]. It is composed of three
phases: assessing relevance, identifying concerns with
the review process, and judging risk of bias. They indi-
vidually assessed each domain by describing the methods
used by the study authors and determined if the study
fulfilled each specific criterion within that domain by an-
swering ‘yes’, ‘probably yes’, ‘probably no’, ‘no’, or ‘no infor-
mation.’A rating of ‘low risk of bias’, ‘high risk of bias’, or
‘unclear risk of bias’ was assigned to the overall domain
after taking the fulfillment of each criterion into account.
In some instances, where there was not enough evidence
to support the ROBIS domains, it was assessed as un-
clear. Similar to the ROBIS tool, the AMSTAR tool, is
used to assess the methodological quality of systematic
reviews [21]. A total of 11 questions were answered with
‘yes’, ‘no’, ‘can’t answer’, or ‘not applicable’. An overall
score was calculated by adding up the number of items
answered with ‘yes’ which would form the numerator.
The denominator was calculated by subtracting the
number of ‘not applicable’ answers from 11, the total
number of questions. A score of three and under was
assigned a low quality. A score between four to eight
was assigned a medium quality. A score of nine and
above was assigned a high quality [21]. For both quality
assessment tools, any discrepancies in assessment be-
tween the two reviewers were resolved through discus-
sion and consensus. A third reviewer (TY) was
consulted if an agreement could not be reached.
Assessing reporting
The PRISMA checklist was used to check the reporting
of the reviews (Additional file 4) [22]. The 27 checklist
items were answered with ‘yes’, ‘partly’, ‘no’, ‘unclear’, or
‘not applicable.’ The results of the completed checklist
for each of the reviews were compiled into a table. For
the purposes of this study, the total number of items
that was answered ‘yes’ was calculated into an overall
score similar to the AMSTAR assessment.
Data analysis
Two reviewers (AR, KY) independently collated and
verified the extracted data for a descriptive synthesis of
important study characteristics and results.
Inter-rater reliability for both ROBIS and AMSTAR
was calculated using Statistical Package for the Social
Sciences (SPSS) version 24 to determine the level of
consistency between the raters’ responses in using
ROBIS and AMSTAR. Cohen’s kappa was used to
calculate inter-rater reliability across the domains of the
tools and percent agreement was reported as a supple-
ment to provide descriptive statistics as well for a more
comprehensive result. Percent agreement was calculated
by dividing the number of items in agreement by the
total number of items.
The results of the completed assessments of each re-
view using both the ROBIS and AMSTAR tools were
compiled into two tables.
Results
Results of the search and description of included
systematic reviews
A total of 12,213 unique citations were identified
through the literature search after duplicates were re-
moved (Fig. 1). Of these, 12,145 citations were consid-
ered irrelevant after title/abstract screening and were
directly excluded. Full texts were retrieved for 68 studies
and of these, 61 were excluded with reasons (Add-
itional file 5). One abstract without available full-text is
waiting to be assessed. Twenty-eight studies were not
systematic reviews and 23 did not include studies that
targeted participants with comorbidities where at least
one of the chronic illnesses was hypertension or
diabetes.
We included five systematic reviews in this scoping re-
view [23–27] (Fig. 1/Table 2). Three of the five system-
atic reviews included studies with a broad range of
conditions [25–27]. Two reviews reported on hyperten-
sion and diabetes [25, 26]. One review reported on
hypertension and depression [24]. Four reviews reported
on diabetes and depression [23, 24, 26, 27]. For the sys-
tematic reviews that covered a broader scope and
encompassed all chronic diseases in their inclusion cri-
teria, we only extracted the information pertinent to our
review.
Included systematic reviews were published between
2013 and 2016, with two published in 2013, two in 2014,
and one in 2016. To better visualise the overlapping in
inclusion of primary studies in the systematic reviews, a
matrix table was created to present the included studies
in the systematic reviews that focused on depression as a
comorbidity (Additional file 6).
Settings
In Atlantis et al.’s review, all studies were conducted in
United States of America, except one which was con-
ducted in Australia [23]. In Huang et al.’s review, all
studies were conducted in United States of America
[24]. In Joshi et al.’s review, three of the relevant studies
were conducted in Cameroon and one was conducted in
South Africa [25]. In Smith et al.’s review, four of the
relevant studies were conducted in United States of
America, one in Australia, and one in United Kingdom
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[26]. In Watson et al.’s review, all relevant studies were
conducted in United States of America [27].
Study design/population
Atlantis et al. included seven RCTs in its review with a
participant range of 58–417. Huang et al.’s review in-
cluded eight RCTs with a participant range of 58–417.
Joshi et al.’s review consisted of 22 studies, of which four
were relevant, including three before-after studies and
one RCT with a participant range of 221–1343. Smith et
al.’s review consisted of 18 studies, of which six were
relevant, including one cluster RCT, four RCTs, and one
pilot RCT with a participant range of 61–400. Watson et
al.’s review consisted of 12 studies of which three studies
were of relevance, including two RCTs and one pre-
planned sub-group analysis from a separate RCT with a
participant range of 329–417.
Interventions
Brief descriptions for each review are provided in the
characteristics of included systematic reviews (Table 2).
While the interventions of all reviews could be broadly
categorized into collaborative care, each review had a
unique definition of the term. Atlantis et al. searched for
‘coordinated multidisciplinary models of care’ as the
intervention. Based on Gunn et al.’s definition of collab-
orative care, Huang et al. defined the term as interven-
tions that fulfilled the following four criteria: ‘a, a
multi-professional patient care; b, a structured manage-
ment plan; c, scheduled patient follow-up; d, enhanced
inter-professional communication’ [28]. Joshi et al. fo-
cused on task-shifting, which meant a task usually per-
formed by physicians is shifted to a different cadre of
health care providers. However, since the interventions
aimed to integrate health service delivery, we deemed it
relevant to our scoping review. Smith et al. targeted
‘professional-, organizational-, or patient-oriented inter-
ventions’ based in primary care or community settings
which aimed to improve outcomes for people with
multi-morbidity. Watson et al. searched for
practice-based interventions that ‘target[ed] the care
process within a system of care and work[ed] to improve
Fig. 1 PRISMA flow chart
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depression or both depression and chronic medical con-
ditions’. All of the reviews included interventions that
focused on vertical integration and clinical integration,
and four on professional integration.
Comparison
In the majority of included reviews, the comparison was
usual care or enhanced usual care, however Watson et
al. also included other practice-based interventions.
Usual care was defined by each study, but in general,
usual care was defined by conventional/general treat-
ments in the primary care setting. On the other hand,
patients under enhanced usual care generally would re-
ceive selective parts of the intervention in additional to
their usual care. For patients under the intervention
arm, they received other services, such as acute treat-
ment and relapse prevention, in addition to the services
provided to those in the comparison enhanced care arm
[29].
Outcomes
The included reviews assessed the following outcomes
which could be organized into health and process out-
comes. All the included reviews reported on health out-
comes, while four of the five reviews reported on
process outcomes. Our pre-specified health outcomes
included all-cause mortality and disease specific morbid-
ity. One review reported on all-cause mortality [27] and
all of the reviews reported on disease specific morbidity.
Outcomes reported under disease specific morbidity in-
cluded depression outcomes [24, 26, 27], cholesterol
levels [26], diabetes (HbA1c levels) clinical outcome [23,
24, 26, 27], effect of depression remission [23], symptom
improvement for depression and diabetes [27], systolic
blood pressure [26], and control for hypertension [25].
Our pre-specified process outcomes included access to
health care, continuity of care, quality of care, cost of
care, and user-views of care recipients. Two reviews re-
ported on access and utilisation of healthcare services
[25, 26]. One review reported on quality of care [27].
One review reported on cost of care [26]. None of the
reviews reported on continuity of care, or user-views of
care recipients. Additional outcomes that did not match
our pre-specified outcomes were not included in our
findings.
Risk of bias of included systematic reviews
A summary assessment of the risk of bias of the in-
cluded reviews can be found in Table 3. Overall, two of
the five reviews were judged as having an overall low
risk of bias after an evaluation of all domains using the
ROBIS quality assessment tool. Three of the reviews
were judged to have an overall high risk of bias.
According to the AMSTAR tool, risk of bias was
judged to be medium (overall scores ranging from 5 to
8) in three reviews and high (overall scores ranging from
9 to 11) in two reviews. Table 4 presents a summary of
risk of bias for all included reviews using AMSTAR.
Comparison of risk of bias assessment using ROBIS and
AMSTAR
In comparing the results of the quality assessments be-
tween ROBIS (Table 3) and AMSTAR (Table 4), all three
reviews graded with an overall high risk of bias for
ROBIS were judged to have a medium quality score
from AMSTAR (Table 5). Meanwhile, the two reviews
graded with an overall low risk of bias for ROBIS were
assigned a high-quality score from AMSTAR. The extent
of the agreement between the ROBIS and AMSTAR
scores can also be explored by comparing the risk of bias
items used in both tools (Additional file 7).
Comparison of reporting using PRISMA
The three reviews with an overall high risk of bias for
ROBIS and medium AMSTAR quality scores received
scores of 10, 19, and 22 out of 27 for PRISMA (Table 6)
respectively. The two reviews with an overall low risk of
bias for ROBIS and high AMSTAR quality scores received
scores of 19 and 26 out of 27 for PRISMA respectively.
Inter-rater reliability of ROBIS and AMSTAR
ROBIS demonstrated very poor inter-rater reliability
with the majority of the questions scoring poor or no
agreement. AMSTAR demonstrated better inter-rater re-
liability when compared to ROBIS, with majority of
kappa values of questions in slight agreement or better
(Additional files 8 & 9). However most of the kappa
values were not statistically significant (p > 0.05).
Overlap of studies included in systematic reviews
The considerable overlap in the studies included within
the four systematic reviews that focused on diabetes and
depression is presented in Additional file 6 where a col-
lective total of 32 studies were included in the reviews
but relate only to 19 separate studies. Ten of the studies
were included in more than one review.
Findings on the effects of integrated care
Findings on the effect of integrated care can also be
found in Table 7.
Integrated care for depression and diabetes
Health outcomes
Risk of all-cause mortality One review reported on the
risk of all-cause mortality. Watson et al. did not find any
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difference between collaborative and usual care for risk
of all-cause mortality at 6 months (RD 0.00, 95%CI -0.02
to 0.02, 7 studies) and 12 months (RD 0.00, 95%CI -0.02
to 0.01, 7 studies). Of the seven studies included in the
6- and 12-month meta-analyses, two included partici-
pants with diabetes and depression.
Depression
Three reviews reported on outcomes linked to depres-
sion. Atlantis et al., Huang et al., Smith et al., and Wat-
son et al. found that intervention groups had better results
on various depression-related outcomes, such as response
and remission, compared to the usual care groups.
Table 3 Summary of risk of bias for all included reviews using ROBIS
Study Domain 1: Study
eligibility criteria*
Domain 2:
Identification
and selection
of studies^
Domain 3: Data
collection and
study appraisal#
Domain 4: Synthesis
and findings+
Overall risk of
bias of review
Justification
Atlantis 2014 [23] High Unclear High High High D1: Eligibility criteria lacked detail
D2: Unclear whether authors searched
for unpublished or ongoing studies and
whether selection of studies was
completed independently or in duplicate
D3: Concerns raised about data extraction
and risk of bias assessment
D4: Risk of bias was not taken into
consideration when conclusions
were formed
Huang 2013 [24] High High High High High D1: No published protocol
D2: Did not include sources for
unpublished reports in search
D3: No information on data extraction
and risk of bias assessment for two of the
studies included in qualitative synthesis
D4: Results might have not been reported
in light of risk of bias
Joshi 2014 [25] High High High High High D1: No protocol and lack of specific
details on eligibility criteria
D2: Did not consider other methods of
searching for unpublished literature
D3: Lack of information on quality
assessment
D4: Did not pre-specify methods of data
analysis. Risk of bias not adequately
assessed or reported with results
Smith 2016 [26] Low Low Low Low Low No concerns
Watson 2013 [27] Low Low Low Low Low The review’s eligibility criteria are limited
to studies in the English language;
however overall there is no concern.
After deliberation, all review authors
judged this review as a low risk of bias.
*Questions from Domain 1:
1.1 Did the review adhere to pre-defined objectives and eligibility criteria?
1.2 Were the eligibility criteria appropriate for the review question?
1.3 Were eligibility criteria unambiguous?
1.4 Were all restrictions in eligibility criteria based on study characteristics appropriate (e.g. date, sample size, study quality, outcomes
measured)?
1.5 Were any restrictions in eligibility criteria based on sources of information appropriate (e.g.publication status or format, language,
availability ofdata)?
^Questions from Domain 2:
2.1 Did the search include an appropriate range of databases/electronic sources for published and unpublished reports?
2.2 Were methods additional to database searching used to identify relevant reports?
2.3 Were the terms and structure of the search strategy likely to retrieve as many eligible studies as possible?
2.4 Were restrictions based on date, publication format, or language appropriate?
2.5 Were efforts made to minimise error in selection of studies?
#Questions from Domain 3:
3.1 Were efforts made to minimise error in data collection?
3.2 Were sufficient study characteristics available for both review authors and readers to be able to interpret the results?
3.3 Were all relevant study results collected for use in the synthesis?
3.4 Was risk of bias (or methodological quality) formally assessed using appropriate criteria?
3.5 Were efforts made to minimise error in risk of bias assessment?
+Questions from Domain 4:
4.1 Did the synthesis include all studies that it should?
4.2 Were all pre-defined analyses reported or departures explained?
4.3 Was the synthesis appropriate given the nature and similarity in the research questions, study designs and outcomes across included studies?
4.4 Was between-study variation (heterogeneity) minimal or addressed in the synthesis?
4.5 Were the findings robust, e.g. as demonstrated through funnel plot or sensitivity analyses?
4.6 Were biases in primary studies minimal or addressed in the synthesis?
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Atlantis et al. found improved standardised depression
outcomes in collaborative care group in comparison to
the usual care group (SMD -0.32, 95%CI -0.53 to − 0.11,
7 studies). The sensitivity analyses considered the fixed
effects model, exclusion of lower quality studies, exclu-
sion of study outside of USA, exclusion of studies that
integrated diabetes care, exclusion of studies that consid-
ered lifestyle risk factors, and exclusion of studies with
less than duration of 1 year. The pooled standardised
mean difference (SMD) remained similar except after
the exclusion of lower quality studies (SMD -0.17,
95%CI -0.35 to 0.00, 4 studies).
Smith et al. found a decrease in depression scores
(SMD -0.41 95%CI -0.63 to − 0.20, 6 studies) for partici-
pants receiving collaborative care compared to usual
care. Four studies included in the meta-analysis included
participants with diabetes and depression. The standar-
dised effect sizes (SESs) for depression in PHQ-9 out-
comes ranged from 0.09 to 2.24. Five of the nine
outcomes suggested moderate to large effect sizes. Three
of the studies included participants with diabetes and
depression.
Huang et al. reported an increase in treatment response
rate (RR 1.33, 95%CI 1.05 to 1.68, 4 studies) at the end of
follow-up for participants in the intervention group when
compared to those in the control group. In pooling the
mean proportion, Huang et al. found that 44.8% of pa-
tients in the intervention group had treatment responses
as compared to 34.3% of patients in the control group. At
6-month follow-up, collaborative care demonstrated sig-
nificant beneficial effect (RR 1.64, 95%CI 1.28 to 2.10, 4
studies). And at 12-month follow-up, collaborative care
also demonstrated significant beneficial effect (RR 1.42,
95%CI 1.14 to 1.76, 4 studies).
Huang et al. also found that collaborative care had
a non-significant effect on the rate of depression re-
mission (RR 1.15, 95%CI 0.87 to 1.52, 2 studies). At
6-month follow-up, collaborative care demonstrated a
significant increase in depression remission (RR 1.33,
95%CI 1.01 to 1.75, 2 studies). However, it should be
noted that although both studies found an increased
treatment response in the intervention group, neither
was significant. At 12-month follow-up, it was shown
that collaborative care had a non-significant effect on
depression remission (RR 1.20, 95%CI 0.93 to 1.55, 2
studies).
Watson et al. also reported remission of depression in
favour of collaborative care at 6 months (RD 0.123,
Table 5 Agreement between ROBIS and AMSTAR
Systematic review ROBIS risk of bias assessment grade AMSTAR quality assessment grade
Atlantis 2014 [23] High risk of bias Medium quality
Huang 2013 [24] High risk of bias Medium quality
Joshi 2014 [25] High risk of bias Medium quality
Smith 2016 [26] Low risk of bias High quality
Watson 2013 [27] Low risk of bias High quality
Table 4 Summary of risk of bias for all included reviews using AMSTAR
AMSTAR item Atlantis 2014 [23] Huang 2013 [24] Joshi 2014 [25] Smith 2016 [26] Watson 2013 [27]
1. ‘A priori’ design No No Yes Yes Yes
2. Duplicate study selection
and data extraction
Can’t answer Can’t answer No Yes Yes
3. Literature search Yes Yes Yes Yes Yes
4. Status of publication No Can’t answer No Yes Yes
5. List of studies Yes No No Yes Yes
6. Characteristics of
included studies
Yes Yes Yes Yes Yes
7. Scientific quality Yes Yes No Yes Yes
8. Formulation of conclusion No No No Yes Yes
9. Methods used to
combine findings
Yes Yes Yes Yes Yes
10. Likelihood of publication bias Yes Yes No Yes No
11. Conflict of interest No Can’t answer No No Yes
Quality score 6 5 4 11 10
Quality rating Medium Medium Medium High High
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95%CI 0.064 to 0.183, 3 studies), 12 months (RD 0.077,
95%CI 0.016 to 0.137, 3 studies), 18 months (RD 0.075,
95%CI 0.013 to 0.136, 3 studies), and 24 months (RD
0.045, 95%CI -0.023 to 0.113, 3 studies). Of the studies
included in each of the 6, 12, 18, and 24 months
meta-analyses, one included participants with diabetes
and depression.
Watson et al. reported reduction (of at least 50%) in
Mental Health score in favour of collaborative care at
6 months (RD 0.20, 95%CI 0.14 to 0.26, 9 studies),
12 months (RD 0.17, 95%CI 0.12 to 0.23, 7 studies), and
18 months (RD 0.12, 95%CI 0.02 to 0.22, 3 studies). Of
the nine studies included in the meta-analysis at the
6-month follow-up, four of them included participants
with diabetes and depression. Of the seven studies in-
cluded in the meta-analysis at the 12-month follow-up,
three of them included participants with diabetes and
depression. Of the three studies included in the
meta-analysis at the 18-month follow-up, one included
participants with diabetes and depression.
Table 6 Summary of completed PRISMA checklist for all included reviews
PRISMA checklist item Atlantis 2014 [23] Huang 2013 [24] Joshi 2014 [25] Smith 2016 [26] Watson 2013 [27]
Title
1. Title Yes Yes Yes Yes Yes
Abstract
2. Structured summary Yes Yes Yes Yes Yes
Introduction
3. Rationale Yes Yes Yes Yes Yes
4. Objectives Yes Yes Yes Yes Yes
Methods
5. Protocol and registration No Yes Yes Yes Yes
6. Eligibility criteria Yes Yes Yes Yes Yes
7. Information sources Yes Yes Yes Yes Yes
8. Search Yes Yes No Yes Unclear
9. Study selection Yes Yes No Yes Yes
10. Data collection process Partly Partly No Yes Yes
11. Data items No Yes No Yes Yes
12. Risk of bias in individual studies Partly Yes No Yes Yes
13. Summary measures Yes Yes N/A Yes Yes
14. Synthesis of results Yes Yes No Yes Yes
15. Risk of bias across studies Yes Yes No Yes Unclear
16. Additional analyses Partly Yes No Yes Yes
Results
17. Study selection Yes Yes Not adequate Yes Yes
18. Study characteristics Yes Yes Yes Yes Yes
19. Risk of bias within studies Partly Yes No Yes Unclear
20. Results of individual studies Yes Yes No Yes Yes
21. Synthesis of results Yes Yes N/A Yes Partly
22. Risk of bias across studies No N/A No Yes No
23. Additional analysis Yes N/A N/A N/A No
Discussion
24. Summary of evidence Yes Yes Yes Yes Partly
25. Limitations Partly Yes Partly Yes Yes
26. Conclusions Yes Partly Partly Yes Yes
Funding
27. Funding Yes No Yes Yes Partly
Number of items included (yes) 19/27 22/27 10/27 26/27 19/27
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Cholesterol levels
One review reported on cholesterol levels. Smith et al.
included two studies that reported on cholesterol levels.
While a RCT found a reduction in low-density lipopro-
tein cholesterol, another RCT did not find any meaning-
ful difference (SES ranges 0.22 to 0.26).
Diabetes clinical outcomes (HbA1c level)
Four reviews reported on clinical outcomes linked to
diabetes. Atlantis et al., Huang et al., Smith et al., and
Watson et al. reported on HbA1c levels and all of them
found reduction of HbA1c levels favouring intervention.
Atlantis et al. found that collaborative care significantly
reduced HbA1c levels in comparison to usual care (WMD
-0.33, 95%CI -0.66 to 0.00%, 7 studies). Sensitivity analyses
showed a slight decrease of pooled weighted mean differ-
ence (WMD) in the fixed effect model (WMD -0.21,
95%CI -0.37 to − 0.05, 7 studies). In addition, it was no
longer statistically significant after the exclusion of each of
the subgroups of studies (lower quality, outside of USA,
integrated diabetes care, consideration of lifestyle risk
factors, less than duration of 1 year).
Huang et al. calculated the mean difference (MD) and
reported a non-significant reduction of HbA1c levels in
Table 7 Findings of included studies
Comorbid
conditions
Type of outcome Findings
Diabetes
and
depression
Risk of all-cause mortality 6 months: RD 0.00, 95%CI -0.02
to 0.02, 2/7 studies of
relevance (Watson 2013)
12 months: RD 0.00, 95%CI
-0.02 to 0.01, 2/7 studies of
relevance (Watson 2013)
Depression Depression scores
SMD −0.32, 95%CI -0.53 to
−0.11, 7 studies (Atlantis 2014)
SMD − 0.41 95%CI -0.63 to −
0.20, 6 studies; 4 of relevance
(Smith 2016)
Response rate
6 months: RR 1.64, 95%CI 1.28
to 2.10, 4 studies (Huang 2013)
12 months: RR 1.42, 95%CI 1.14
to 1.76, 4 studies (Huang 2013)
End of follow-up: RR 1.33,
95%CI 1.05 to 1.68, 4 studies
(Huang 2013)
Remission
6 months: RR 1.33, 95%CI 1.01
to 1.75, 2 studies (Huang 2013)
RD 0.123, 95%CI 0.064 to 0.183,
3 studies (Watson 2013)
12 months: RR 1.20, 95%CI 0.93
to 1.55, 2 studies (Huang 2013)
RD 0.077, 95%CI 0.016 to 0.137,
3 studies (Watson 2013)
18 months: RD 0.075, 95%CI
0.013 to 0.136, 3 studies
(Watson 2013)
24 months: RD 0.045, 95%CI
-0.023 to 0.113, 3 studies
(Watson 2013)
End of follow-up: RR 1.15,
95%CI 0.87 to 1.52, 2 studies
(Huang 2013)
Reduction (of at least 50%) in
Mental Health score
6 months: RD 0.20, 95%CI 0.14
to 0.26, 4/9 studies of
relevance (Watson 2013)
12 months: RD 0.17, 95%CI
0.12 to 0.23, 3/7 studies of
relevance (Watson 2013)
18 months: RD 0.12, 95%CI
0.02 to 0.22, 1/3 studies of
relevance (Watson 2013)
Diabetes clinical
outcome (HbA1c level)
6 months: MD − 0.06, 95%CI
-0.24 to 0.12, 4 studies (Huang
2013)
MD 0.13, 95%CI -0.22 to 0.48, 3
studies (Watson 2013)
12 months: MD − 0.07, 95%CI
-0.28 to 0.13, 4 studies (Huang
2013)
MD 0.24, 95%CI -0.14 to 0.62, 3
studies (Watson 2013)
End of follow-up:
WMD − 0.33, 95%CI -0.66 to
0.00%, 7 studies (Atlantis 2014)
MD − 0.13, 95%CI -0.46 to 0.19,
7 studies (Huang 2013)
WMD − 0.33, 95%CI -0.66 to
0.00%, 7 studies (Smith 2016)
Table 7 Findings of included studies (Continued)
Comorbid
conditions
Type of outcome Findings
Effect of depression
remission on HbA1c
SMD for depression scores
were unable to predict the
WMD in HbA1c values;
p − 0.828, coefficient 0.19,
95%CI -1.93 to 2.31, 7 studies
(Atlantis 2014)
Symptom improvement Watson et al. reported greater
depression symptom
improvement scores in
intervention groups at
6 months: MD 0.38, 95%CI 0.24
to 0.51, 3/5 studies of
relevance (Watson 2013)
12 months: MD 0.38, 95%CI
0.30 to 0.46, 3/5 studies of
relevance (Watson 2013)
24 months: MD 0.18, 95%CI
0.10 to 0.26, 2/3 studies of
relevance (Watson 2013)
Systolic blood pressure MD −3.10, 95%CI -7.26 to 1.06,
5 studies (Smith 2016)
Access and utilisation of
healthcare services
12 months: range: 42 to 84%;
usual care range: 16 to 33%, 3/
4 studies of relevance
(Watson 2013)
Quality of care in terms of
mental health treatment
satisfaction
12 months: RD 0.205, 95%CI
0.112 to 0.299, 3/4 studies of
relevance (Watson 2013)
24 months: RD 0.14, 95%CI
0.06 to 0.21, 1/3 studies of
relevance (Watson 2013)
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favour of collaborative care (MD -0.13, 95%CI -0.46 to
0.19, 7 studies) at the end of follow-up. At 6-month
follow-up, a non-significant reduction on HbA1c levels
in favour of collaborative care (MD -0.06, 95%CI -0.24
to 0.12, 4 studies) was reported. At 12-month follow-up,
a non-significant reduction on HbA1c levels in favour of
collaborative care (MD -0.07, 95%CI -0.28 to 0.13, 4
studies) was reported.
Smith et al. reported that collaborative care signifi-
cantly reduced HbA1c levels in comparison to usual care
(WMD -0.33, 95%CI -0.66 to 0.00%, 7 studies).
Watson et al. found reduction in HbA1c levels in
favour of collaborative care (MD 0.13, 95%CI -0.22 to
0.48, 3 studies) at 6 months. And at 12 months, reduc-
tion in HbA1c levels was still in favour of collaborative
care (MD 0.24, 95%CI -0.14 to 0.62, 3 studies).
Effect of depression remission on HbA1c
One review reported on the effect of depression remis-
sion on diabetes. Atlantis et al. found that there was no
association between the SMD in depression outcomes
and the weighted mean difference (WMD) in HbA1c
values. SMD for depression scores were unable to pre-
dict the WMD in HbA1c values (p − 0.828, coefficient
0.19, 95%CI -1.93 to 2.31, 7 studies).
Symptom improvement for depression and diabetes
One review reported on symptom improvement for de-
pression and diabetes. Watson et al. reported greater de-
pression symptom improvement scores in intervention
groups at 6 months (MD 0.38, 95%CI 0.24 to 0.51, 5
studies), 12 months (MD 0.38, 95%CI 0.30 to 0.46, 5
studies), and 24 months (MD 0.18, 95%CI 0.10 to 0.26, 3
studies) compared to the control groups of usual care.
Of the five studies included in the 6-month and
12-month meta-analyses, three of them included partici-
pants with diabetes and depression. Of the three studies
included in the 24-month meta-analysis, two of them in-
cluded participants with diabetes and depression. The
benefits last through 24 months but a reduction in the
magnitude of benefit was also mentioned.
Systolic blood pressure
One review reported on systolic blood pressure. Smith et
al. reported on improvement of systolic blood pressure in
favour of the intervention group (MD -3.10, 95%CI -7.26
to 1.06, 5 studies). The SESs varied from 0.01 to 1.12, but
only one of the studies had an SES greater than 0.5.
Process outcomes
Access and utilisation of healthcare services
Two reviews reported on access and utilisation of
healthcare services. Smith et al. found five studies that
reported on outcomes of health services utilisation, of
which one RCT was of relevance to our review. The
study did not find any difference in admission-related
outcomes. However, it should be noted that the numbers
of admission were very small.
Watson et al. reported that participants in the inter-
vention group used more mental health services in com-
parison to the control group at 12 months (range: 42 to
84%; usual care range: 16 to 33%, 4 studies). Three of
the studies included participants with depression and
diabetes.
Costs
One review reported on costs linked to the intervention.
Smith et al. provided data on five studies that reported
on costs, of which one was of relevance to our review.
An RCT found that the direct mean medical costs for
TeamCare intervention for 12 months were $1224 USD
per individual. In a later RCT by the same researchers,
an economic analysis was conducted. They found that
the intervention led to an increase of 114 days in
depression-free days and an estimated difference of
0.335 quality-adjusted life years (QALYs) (95% CI -0.18
to 0.85).
Quality of care
One review reported on quality of care. Watson et al. re-
ported on mental health treatment satisfaction in favour
of collaborative care at 12 months (RD 0.205, 95%CI
0.112 to 0.299, 4 studies) and 24 months (RD 0.14,
95%CI 0.06 to 0.21, 3 studies). Of the four studies in-
cluded in the 12-month meta-analysis, three of them in-
cluded participants with diabetes and depression. Of the
three studies included in the 24-month meta-analysis,
one included participants with diabetes and depression.
Integrated care for diabetes and hypertension
Health outcomes
Achievement of control for hypertension
One review reported on control for hypertension. Joshi
et al. reported on a before-after study and found that
trained non-physician healthcare workers (NPHWs),
without the input of physicians but assistance from
treatment protocols, were able to achieve control of 68%
of patients with hypertension and 82% of individuals
with diabetes.
Process outcomes
Access and utilisation of healthcare services
One review reported on access and utilisation of health-
care services. Joshi et al. found four studies that reported
task-shifting improved access to healthcare at the com-
munity level. Of the four studies, three included partici-
pants with hypertension and diabetes. However, it must
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be noted that the metric to evaluate access was not de-
scribed in most studies.
Discussion
We conducted a scoping review on integration of care
for hypertension and diabetes and identified five system-
atic reviews that were published from 2013 to 2016.
Overall, collaborative care was better in comparison to
usual care with regards to health and process outcomes
for both depression and diabetes and hypertension and
diabetes. Four of the included reviews focused on de-
pression and diabetes. There was no significant differ-
ence in the outcomes for collaborative care for
depression and diabetes with respect to risk to all-cause
mortality and admission-related outcomes. Collaborative
care has demonstrated better outcomes in depression
scores, depression treatment response, depression remis-
sion, HbA1c levels, symptom improvements, systolic
blood pressure, and mental health treatment satisfaction.
There were mixed results with regard to cholesterol out-
comes. No association was found between effect of de-
pression remission and HbA1c levels. One included
review focused on hypertension and diabetes. The use of
task-shifting in collaborative care demonstrated im-
proved access to care at the community level.
The majority of the primary studies included in the
systematic reviews were conducted in high income
countries, such as U.S.A., U.K., and Australia. Only one
review [15] included primary studies conducted in
low-and middle-income countries in SSA. None of the
reviews focused on collaborative care for communicable
and non-communicable diseases. Considering
sub-Saharan Africa’s history of the HIV/AIDS and tuber-
culosis (TB) epidemics along with the recent rise of the
quadruple burden of diseases (cardiovascular diseases,
diabetes, chronic respiratory conditions, and cancer), it
is important to direct future research on integration of
care to cover comorbid communicable and
non-communicable diseases. Possible outcomes to evalu-
ate would include mortality rate, clinical outcomes spe-
cific to the individual diseases, symptom improvement,
effect of one disease on another, quality of care, etc.
Our findings, particularly with respect to depression
outcomes, were consistent to those reported in the
current general literature on collaborative care programs
for general, non-specific comorbid chronic disease pro-
grams. The evidence from primary studies and reviews
demonstrated that collaborative care is more effective in
improving short- and long-term depression outcomes
and decreasing symptoms [30, 31]. Recent overviews
noted that interventions targeted at specific combina-
tions of comorbidities for patients with chronic illnesses
were more likely to be more effective than interventions
that target single specific diseases. In addition, these
multi-component interventions were found to improve
patient self-management outcomes and process-of-care
behaviours [32, 33]. The agreement between our findings
and that of other systematic reviews demonstrated that
collaborative care, overall, are effective regardless of the
comorbidities involved.
Integration of care has been demonstrated and de-
scribed in multiple care models, such as the Chronic
Care Model (CCM), collaborative care models, inte-
grated/comprehensive-care programs, and other
multi-component chronic-disease management. Al-
though our scoping review had only included reviews
that mainly focused on collaborative care, research on
all relevant models demonstrating integration of care
should be considered in relation to our findings. For ex-
ample, a rapid synthesis of comparison of
multi-component chronic-disease programs to
disease-specific programs conducted by the McMaster
Health Forum identified the following factors to be key
facilitators to the implementation of CCM models:
strong network support, increased communication be-
tween healthcare providers and organizations, creation
of organizational culture that focuses on multidisciplin-
ary and patient-centred care, recognition and commit-
ment to efforts put forth by organizations and providers
to induce change, implementation of structural and pol-
icy changes, leadership, and education for providers on
CCM interventions and their effectiveness [33]. The
CCM is defined as “an organizational approach to caring
for people with chronic disease in a primary care set-
ting.” It is a “population-based and creates practical, sup-
portive, evidence-based interactions between an
informed, activated patient and a prepared, proactive
practice team [34].” It shares many similar elements with
collaborative care, such as self-management support, de-
livery system design, decision support, and clinical infor-
mation systems [34]. Noting the similar common
components of both as well as the similarity of elements
in the reviews used in our findings, the identified key fa-
cilitators to CCM may also be applicable to collaborative
care model.
During the process of data extraction, we found that
the interventions were unclear and not well-described,
despite many of them being rather complex in nature.
Furthermore, there was no consistency of descriptions of
interventions between systematic reviews. Future sys-
tematic reviews on integrated care should describe their
interventions in more detail.
In addition to the health and process outcomes that
were identified in our review, Thota et al. also reviewed
additional benefits such as the positive impact on pa-
tient’s job retention and work productivity, as well as
their adherence to treatment [31]. To gain a more holis-
tic review of the implications of collaborative care, this
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review also identified the potential harm brought on by
the intervention and the potential barriers to implemen-
tation. By further supplementing the results of Thota
et al.’s review with a systematic review by Watt et al., we
can gain a better understand behind the causes of suc-
cesses and failures behind integrated care. Watt et al.
identified five themes on the facilitators and barriers to in-
tegration of HIV and chronic disease services and they in-
cluded (1) ‘formal and informal productive relationships
throughout the system’, (2) ‘need for adequate and appro-
priately skilled and incentivized health workers’, (3) ‘need
for supportive institutional structures and dedicated re-
sources’, (4) political leadership, ‘effective managerial over-
sight and organizational culture’, and (5) ‘placing the
patient at the centre of service delivery’ [35]. From these
studies, it could be seen that the potential implications of
collaborative care should be considered in addition to its
effectiveness in order to gain a comprehensive under-
standing of its feasibility. A future update of this review
should also examine factors influencing implementation
by including qualitative studies in addition to RCTs.
In assessing the overall risk of bias, ROBIS placed
similar consideration for each of the domains as mea-
sured by the number/distribution of assessment items,
while AMSTAR focused primarily on study selection,
data collection, and synthesis and findings. With only an
overlap of six assessment items which were included in
both the AMSTAR and ROBIS tools, this suggested that
the two tools included different aspects for consideration
in their assessment. The higher number of discrepancies
in assessment items for ROBIS may be attributed to its
complex and highly divided grading scale. However, des-
pite the high number of discrepancies, there was general
agreement between the two reviewers on the overall risk
of bias of the majority of systematic reviews.
There seemed to be no correlation between the
PRISMA checklist score and the quality rating of a re-
view. This reaffirmed the previous notion that the
reporting checklist and the assessment tools are distinct
instruments. The reporting checklist ensured the pres-
ence of relevant components of a systematic review but
however, had no bearing on the quality of the compo-
nents. Therefore, it is possible to achieve a high PRISMA
score but a low quality in risk of bias score. Conversely,
it is impossible to achieve a low PRISMA score but a
high quality in risk of bias score, because the quality of
the component cannot be assessed if it is not present.
The quality of the evidence and subsequently the re-
sults of a systematic review are unquestionably import-
ant, but it may be of little use to the reader if they do
not apply to the reader’s question. Results of a study
conducted under a certain setting may not necessarily
be relevant to other settings. And as applicability of the
results were not considered in either AMSTAR or
ROBIS tools, additional instruments such as the SUP-
PORT tool should be used to supplement the risk of bias
assessments [36].
With regards to the findings from the inter-rater reli-
ability analysis, the poor inter-rater agreement suggested
that assessing risk of bias using ROBIS as a first-time
user may be quite difficult. This was consistent with the
authors’ experiences with the tool. However, it was not
surprising that the inter-rater agreement for ROBIS was
much lower than that of AMSTAR given the finer dis-
crimination the ROBIS rater must differentiate based on
the data [37]. It should be noted that ROBIS adopted a
non-linear, semi-ordinal/nominal scale in its rating an-
swer options which could be justified in using either
kappa or weighted kappa in our analysis. We decided to
use kappa for both AMSTAR and ROBIS for the pur-
pose of direct comparison. Given the poor inter-rater
agreement, sensitivity analysis was considered but ultim-
ately, we decided to not pursue it. As the decision to test
for inter-rater reliability was included ad hoc, it was de-
termined that it may be more suitable to keep the ana-
lysis simple and forego the sensitivity analysis.
Robustness of our methodology
Similar to using ROBIS for risk of bias assessment on our
included reviews, we also used its assessment criteria as a
guide to ensure that our scoping review is conducted in a
methodologically sound manner. For example, in phase 2
under the domain of study eligibility criteria, we ensured
that we used appropriate and unambiguous predefined
objectives and eligibility criteria. Next, under the domain
for identification and selection of studies, we included a
wide range of databases and additional search methods to
identify all relevant reviews while selecting the studies in
an independent and duplicate manner to minimize the
risk of errors. In the subsequent domain of data collection
and study appraisal, similar independent and duplicate ef-
forts were made to minimize error in data collection and
risk of bias assessment. And under the final domain of
synthesis and findings, many of the criteria posed in the
signalling questions did not apply as we did not conduct a
meta-analysis. However, the synthesis included all relevant
studies as it should.
Limitations
This scoping review was limited by the small body of lit-
erature available on integration of care in delivery for
hypertension and diabetes. Only five systematic reviews
met the inclusion criteria set a priori. Therefore, this re-
view should be considered as stimulation for further dis-
cussion and research on this matter. In addition, as
previously mentioned, the majority of the included re-
views were composed of primary studies held in higher
income countries and thus the results may not be
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feasible or applicable to the CEBHA+ initiative which is
aimed at a SSA context. With regards to the inter-rater
reliability component of this paper, this analysis was de-
termined ad hoc and the data collected was not opti-
mized for this purpose. And further supporting/
demonstrating the limitation of available literature, the p
values were extremely underpowered with only five stud-
ies included in the analysis. It should be further noted
that the raters had different levels of experience in using
the risk of bias tools which may have resulted in a lower
inter-rater agreement than normal.
Conclusion
The findings from this scoping review have indicated a no-
ticeable knowledge gap in integrated care in delivery-system
interventions for co-morbid hypertension and diabetes
present in the current literature. There is limited evidence
from low-and middle-income countries. Future systematic
reviews should assess the effect of integrated models of care
for non-communicable diseases (such as diabetes and hyper-
tension) and communicable diseases (such as HIV and TB).
Systematic reviews should adequately report on the compo-
nents of the interventions and assess clinical as well as
system-level process outcomes such as access to health care,
continuity of care, quality of care, cost of care, and
user-views of care recipients.
From our comparison of AMSTAR and ROBIS tools, it
could be seen that both were useful and more or less con-
sistent in providing us with overall judgments about risk
of bias. The purpose of such tools is to guide the risk of
bias assessment and given that the most important thing
is to simply consider risk of bias when considering evi-
dence, both tools are adequate in achieving this objective.
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